Comparable amounts of sex steroids are made outside the gonads in men and women: Strong lesson for hormone therapy of prostate and breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 1-2, 2009, Pages 52-56

  Labrie, Fernand ^a   Cusan, Leonello ^a   Gomez, José Luis ^a   Martel, Céline ^a   Bérubé, René ^a   Bélanger, Patrick ^a   Bélanger, Alain ^a   Vandenput, Liesbeth ^b   Mellström, Dan ^b   Ohlsson, Claes ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Combined androgen blockade; Prostate cancer

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; ANTIESTROGEN; ESTROGEN; GLUCURONIDE;

ADULT; AGED; ANDROGEN METABOLISM; ARTICLE; BREAST CANCER; CASTRATION; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; GONAD; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; METABOLITE; POSTMENOPAUSE; PROSTATE CANCER; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASTRATION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GONADAL STEROID HORMONES; GONADS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MODELS, BIOLOGICAL; POSTMENOPAUSE; PROSTATIC NEOPLASMS; SEX CHARACTERISTICS;

EID: 59849125252     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.11.004     Document Type: Article

References (31)

1. Archer D.F., Furst K., Tipping D., Dain M.P., and Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 94 (1999) 498-503
2. Huggins C., and Hodges C.V. Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-307
3. Labrie F., Dupont A., and Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Important Advances in Oncology (1985), J.B. Lippincott, Philadelphia 193-217
4. Labrie F., and Intracrinology. Mol Cell Endocrinol 78 (1991) C113-C118
5. Bélanger B., Bélanger A., Labrie F., Dupont A., Cusan L., and Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 32 (1989) 695-698
6. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., and Tobias J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
7. Poortman J., Thijssen J.H., von Landeghem A.A., Wiegerinck M.A., and Alsbach G.P. Subcellular distribution of androgens and oestrogens in target tissue. J Steroid Biochem 19 (1983) 939-945
8. Nishiyama T., Hashimoto Y., and Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10 (2004) 7121-7126
9. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., Bremner W.J., Gleave M.E., and Nelson P.S. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67 (2007) 5033-5041
10. Caubet J.F., Tosteson T.D., Dong E.W., Naylon E.M., Whiting G.W., Ernstoff M.S., and Ross S.D. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 (1997) 71-78
11. Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
12. Labrie F., Bélanger A., Candas B., Cusan L., Gomez J.L., Labrie C., Luu-The V., and Simard J. GnRH agonists in the treatment of prostate cancer. Endocrine Rev 26 (2005) 361-379
13. Labrie F., Candas B., Gomez J.L., and Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology 60 (2002) 115-119
14. Ueno S., Namiki M., Fukagai T., Ehara H., Usami M., and Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 13 (2006) 1494-1500
15. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 97 (2006) 243-247
16. Rinaldi S., Dechaud H., Biessy C., Morin-Raverot V., Toniolo P., Zeleniuch-Jacquotte A., Akhmedkhanov A., Shore R.E., Secreto G., Ciampi A., Riboli E., and Kaaks R. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 10 (2001) 757-765
17. Taieb J., Mathian B., Millot F., Patricot M.C., Mathieu E., Queyrel N., Lacroix I., Somma-Delpero C., and Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49 (2003) 1381-1395
18. Labrie F., Bélanger A., Bélanger P., Bérubé R., Martel C., Cusan L., Gomez J.L., Candas B., Castiel I., Chaussade V., Deloche C., and Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99 (2006) 182-188
19. Labrie F., Belanger A., Belanger P., Berube R., Martel C., Cusan L., Gomez J., Candas B., Chaussade V., Castiel I., Deloche C., and Leclaire J. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 103 (2007) 178-188
20. Vandenput L., Labrie F., Mellstrom D., Swanson C., Knutsson T., Peeker R., Ljunggren O., Orwoll E., Eriksson A.L., Damber J.E., and Ohlsson C. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res 22 (2007) 220-227
21. Labrie F., Candas B., Dupont A., Cusan L., Gomez J.L., Suburu R.E., Diamond P., Lévesque J., and Bélanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 (1999) 83-91
22. Labrie F., Luu-The V., Bélanger A., Lin S.-X., Simard J., and Labrie C. Is DHEA a hormone? Starling Review. J Endocrinol 187 (2005) 169-196
23. Labrie C., Bélanger A., and Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 (1988) 1412-1417
24. Labrie F., Belanger A., Labrie C., Candas B., Cusan L., and Gomez J.L. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. J Steroid Biochem Mol Biol 107 (2007) 57-69
25. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., and Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
26. Akaza H., Homma Y., Usami M., Hirao Y., Tsushima T., Okada K., Yokoyama M., Ohashi Y., and Aso Y. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 98 (2006) 573-579
27. Labrie F. Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 3 (2007) 584-593
28. Villareal D.T., and Holloszy J.O. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292 (2004) 2243-2248
29. Labrie F., Diamond P., Cusan L., Gomez J.L., Belanger A., and Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82 (1997) 3498-3505
30. Davis S.R., McCloud P., Strauss B.J., and Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21 (1995) 227-236
31. Simon J., Klaiber E., Wiita B., Bowen A., and Yang H.M. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 6 (1999) 138-146